Dicerna Pharmaceuticals (NASDAQ:DRNA) Rating Increased to Buy at BidaskClub

Dicerna Pharmaceuticals (NASDAQ:DRNA) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday, BidAskClub reports.

Other equities analysts have also recently issued reports about the stock. Citigroup upped their price target on shares of Dicerna Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, July 3rd. Zacks Investment Research cut shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 15th. Chardan Capital restated a “buy” rating and issued a $18.00 price target on shares of Dicerna Pharmaceuticals in a research report on Tuesday, August 13th. Cowen restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Tuesday, July 2nd. Finally, ValuEngine cut shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, September 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company. Dicerna Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $21.57.

DRNA stock opened at $16.39 on Friday. The company has a 50 day simple moving average of $14.50 and a 200 day simple moving average of $14.02. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -13.66 and a beta of 2.21. Dicerna Pharmaceuticals has a 1 year low of $9.31 and a 1 year high of $16.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.65 and a quick ratio of 3.65.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.03). Dicerna Pharmaceuticals had a negative net margin of 737.93% and a negative return on equity of 50.30%. The business had revenue of $5.68 million during the quarter, compared to analyst estimates of $10.95 million. On average, equities research analysts anticipate that Dicerna Pharmaceuticals will post -1.31 EPS for the current fiscal year.

In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 14,680 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $13.07, for a total value of $191,867.60. Following the completion of the transaction, the insider now directly owns 9,800 shares in the company, valued at approximately $128,086. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 21.28% of the company’s stock.

Several large investors have recently bought and sold shares of DRNA. University of Notre Dame DU Lac boosted its stake in shares of Dicerna Pharmaceuticals by 215.2% in the 2nd quarter. University of Notre Dame DU Lac now owns 759,949 shares of the biopharmaceutical company’s stock valued at $11,969,000 after purchasing an additional 518,836 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Dicerna Pharmaceuticals by 54.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,152,999 shares of the biopharmaceutical company’s stock valued at $18,160,000 after purchasing an additional 406,960 shares during the last quarter. Nuveen Asset Management LLC bought a new stake in shares of Dicerna Pharmaceuticals in the 2nd quarter valued at $3,994,000. Marshall Wace LLP bought a new stake in shares of Dicerna Pharmaceuticals in the 1st quarter valued at $2,963,000. Finally, Citadel Advisors LLC boosted its stake in shares of Dicerna Pharmaceuticals by 8.1% in the 2nd quarter. Citadel Advisors LLC now owns 2,185,409 shares of the biopharmaceutical company’s stock valued at $34,420,000 after purchasing an additional 163,799 shares during the last quarter. 82.04% of the stock is currently owned by institutional investors.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Article: Why are percentage gainers important?

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.